Nusano News
Nusano’s Jzaneen Lalani Named to Top 50 Women Leaders in Healthcare Technology List
WEST VALLEY CITY, Utah – March 7, 2025 – The Healthcare Technology Report has named Jzaneen Lalani to its Top 50 Women Leaders in Healthcare Technology of 2024 list....
Nusano and GlyTherix Announce Lutetium-177 Supply Agreement
VALENCIA, Calif. and SYDNEY, Australia – Dec. 9, 2024 – Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid...
Nusano Names Medical Radioisotopes Advisory Board
Nusano names five member Medical Radioisotope Advisory Board
Nusano to Present at William Blair Virtual Radiopharmaceuticals Event
VALENCIA, Calif. – November 12, 2024 – Nusano, a physics company transforming the production of radioisotopes, today announced the company’s CEO Chris Lowe will present at William Blair’s Innovators Series: Radiopharmaceuticals virtual event on Thursday, November 14,...
Nusano and Starget Pharma Announce Supply Agreement to Accelerate Smart Targeted Radioligand Development
Image above: Starget Pharma, stargetpharma.comVALENCIA, Calif. and TEL AVIV, Israel – Oct. 17, 2024 – Nusano, a physics company transforming the production of radioisotopes, and Starget Pharma, a clinical-stage biotechnology company developing precision peptide...
Nusano Presenting at Industry Events in October
VALENCIA, Calif. – Oct. 7, 2024 – Nusano, Inc., a physics company transforming the production of radioisotopes, today announced it will speak at three industry conferences in October 2024. Oppenheimer 2nd Annual Targeted Radiopharmaceutical Therapies in...
Nusano Adds to Executive Leadership Team in Advance of 2025 Commercialization
VALENCIA, Calif. – Oct. 3, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced the addition of two executives to support its business commercialization and the availability of non-carrier-added lutetium-177...
Nusano Announces Series C Financing of Over $115M to Commercialize Radioisotopes
Funding supports development and commercialization of broad array of isotopes for medical, commercial and industrial uses VALENCIA, Calif. – Oct. 1, 2024 – Nusano, Inc., a physics company transforming the production of radioisotopes, today announced a Series C...
Nusano and PharmaLogic Announce Strategic Supply Agreement to Enable Current and Emerging Radiopharmaceuticals
Nusano and PharmaLogic announced a supply agreement to provide a more efficient and reliable supply of critical radioisotopes. The agreement will increase access to on-demand radioisotope supplies provided by Nusano for use in pharmaceutical products produced in PharmaLogic’s network of facilities.
Nusano Names D. Scott Holbrook as Chairman of its Board
VALENCIA, Calif. – June 7, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced industry veteran D. Scott Holbrook as chairman of its board. Holbrook is the co-founder of Invivo Molecular Imaging, and currently...
Nusano Expands Executive Management to Support Q1 2025 Radioisotope Commercialization
VALENCIA, Calif. – May 29, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced the addition of three executives to enhance and expand key business process capabilities. These appointments provide additional...
BLOG Posts
MedicalXpress: Researchers develop new method of precisely targeting cancer lesions while protecting healthy tissues
From MedicalXpress: A team of researchers has developed a new method that suppresses the distribution of drugs to...
ICR: ‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancer
News from the United Kingdom's Institute of Cancer Research (ICR) published in The Lancet Oncology reports that...
Case Study: Radioisotope supply challenges affecting prostate cancer treatment
Experts at the Dana-Farber Cancer Institute report patient treatments were delayed by three months due to low supply of 177Lu-PSMA-617.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates